TUCSON, Ariz. and HUNINGUE, France, May 07, 2018 (GLOBE NEWSWIRE) — HTG Molecular Diagnostics, Inc. (Nasdaq:HTGM) (“HTG”), a provider of instruments, reagents and services for molecular profiling applications, and Firalis S.A. (“Firalis”), a provider of bioanalytical services and biomarker-based products and services, today announced a non‑exclusive license and supply agreement (“Agreement”) that will enable Firalis to commercialize a next‑generation sequencing (NGS)‑based theranostic product and services to predict rheumatoid arthritis (RA) patients response to anti‑TNFα therapy, and other research products and services for mRNA profiling of inflammatory‑autoimmune disorders.Continue reading
Category Archives: AZBio News
C-Path receives COA qualification from FDA for the non-small cell lung cancer
Critical Path Institute’s Patient-Reported Outcome Consortium announces its second clinical outcome assessment qualification from the US Food and Drug AdministrationContinue reading
INSYS Therapeutics Initiates Phase 2 Clinical Trial of Cannabidiol (CBD) for Treatment of Prader-Willi Syndrome
Study will evaluate safety and efficacy of company’s CBD product candidate in rare genetic disease characterized by insatiable appetite in childrenContinue reading
New UA Research Study Aims to Predict and Prevent Deadly Disease in Premature Infants
Study aims to develop the first predictive test to identify and prevent necrotizing enterocolitis, a disease that kills thousands of premature babies each year.Continue reading
BIO at 25 – How it all began
The Biotechnology Innovation Organization (BIO) got its start through a need to come together to create one voice for a fledgling industry. So much has happened in 25 years. Watch the video to learn more.Continue reading
Dr. Megha Padi Arrives from String Theory Background at Harvard to Expand Collaboration in Bioinformatics at UA Cancer Center
Megha Padi, PhD, harnesses the computational power of bioinformatics to learn more about cancer and how best to treat it — and empowers other cancer researchers to do the same.Continue reading
INSYS Therapeutics to Advance Clinical Research of Dronabinol Inhalation Using Novel Breath-Actuated Device
INSYS Therapeutics, Inc. (NASDAQ:INSY), a leader in the development, manufacture and commercialization of pharmaceutical cannabinoids and spray technology, today announced plans to advance clinical research of dronabinol inhalation using a novel and patented breath-actuated device—licensed from U.K.-based Senzer Ltd. and accepted by the U.S. Food and Drug Administration (FDA) under an investigational new drug (IND) filing—in the second half of 2018.
Continue reading
HonorHealth and TransMed Systems Collaborate To Accelerate Patient Access To Clinical Trials
Collaboration will accelerate patient access to clinical trials through advanced predictive modeling tools and patient screening technologies
HTG Promotes John Lubniewski to President and Chief Operating Officer
Mr. Lubniewski assumes the role after having served for seven years as Chief Business OfficerContinue reading